← back to search

Tianni Zhou

California State University, Long Beach · US
Area of research
Genetics · Pulmonary and Respiratory Medicine
Research interest
Research interests include Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Meningioma and schwannoma management, and Neuroblastoma Research and Treatments.
h-index
30
citations
4,072
works
44
NIH funding
primary concept
Medicine
email

Recent publications

Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children’s Oncology Group
Neuro-Oncology 2025cited by 5position: middledoi
Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children’s Oncology Group Trial ACNS0333
Journal of Clinical Oncology 2020cited by 191position: middledoi
Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma
Journal of Clinical Oncology 2019cited by 229position: middledoi
EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP ACNS0332 TRIAL
Neuro-Oncology 2018cited by 0position: middledoi
PDCT-05. MOLECULAR DIAGNOSTICS REVEAL 60% HIGHER SURVIVAL FOR MOLECULARLY-VERIFIED VERSUS HISTOPATHOLOGICALLY-DIAGNOSED PEDIATRIC SUPRATENTORIAL CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS AND PINEOBLASTOMAS; A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP ACNS0332 TRIAL
Neuro-Oncology 2017cited by 2position: middledoi
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study
Neuro-Oncology 2016cited by 179position: middledoi
Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average‐risk medulloblastoma: COG A9961
Pediatric Blood & Cancer 2013cited by 93position: middledoi
Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL).
Journal of Clinical Oncology 2012cited by 13position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Peter C. Burger · Sidney Kimmel Comprehensive Cancer Center5 papers (2016–2020)Chris Williams‐Hughes · Children's Oncology Group4 papers (2017–2020)Amar Gajjar · Mills Peninsula Health Services4 papers (2013–2020)Roger J. Packer · Jefferson Hospital for Neuroscience3 papers (2013–2018)Ian F. Pollack · University of Pittsburgh3 papers (2016–2020)Linda Heier · University Hospital Bonn2 papers (2017–2018)Jeff M. Michalski · Washington University in St. Louis2 papers (2017–2018)David Capper · German Cancer Research Center2 papers (2017–2018)Eugene Hwang · Center for Cancer and Blood Disorders2 papers (2017–2018)Stefan M. Pfister · Université du Québec2 papers (2017–2018)Sarah Leary · Neurological Surgery2 papers (2017–2018)Catherine A. Billups · Cancer Research And Biostatistics2 papers (2017–2018)Lukas Chávez · Children’s Institute2 papers (2017–2018)F. Daniel Armstrong · University of Miami Hospital2 papers (2013–2019)Alok Jaju · Great Ormond Street Hospital2 papers (2017–2018)Maryam Fouladi · University of Cincinnati2 papers (2018–2020)Marcel Kool · European Bioinformatics Institute2 papers (2017–2018)Sebastian Brabetz · Champions Oncology (United States)2 papers (2017–2018)Mark Krailo · University of Southern California2 papers (2016–2020)Yimei Li · Shanghai Institute of Technology2 papers (2017–2018)